Inozyme PharmaÂ Inc (INZY)

Name: Inozyme PharmaÂ Inc (INZY) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Inozyme PharmaÂ Inc (INZY)

Stock Card

$4.00

$0.00 (0.00%)

As on 02-Jul-2025 09:30EDT

Market cap

$258 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

8.1

Div. Yield

0 %

Inozyme PharmaÂ Inc (INZY) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.00 High: 4.00

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-4.3
Debt to Equity

0.6
Book Value

$--
EPS

$-1.7
Face value

--
Shares outstanding

64,561,800

6 Years Aggregate

CFO

$-240.81 Mln

EBITDA

$-287.37 Mln

Net Profit

$-274.45 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Inozyme PharmaÂ Inc (INZY)	44.4	0.8	359.8	-9.3	-4.8	--	--
BSE Sensex^*	-10.1	-2.5	2.0	-5.0	5.2	5.7	10.3
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 02-Jul-2025 | *As on 03-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021
Inozyme PharmaÂ Inc (INZY)	-34.7	305.7	-84.6	-67.0
S&P Small-Cap 600	7.0	13.9	-17.4	25.3
BSE Sensex	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Inozyme PharmaÂ Inc (INZY)	4.0	258.3	0.0	-106.7	--	-186.3	--	8.1
SpringWorks Therapeutics (SWTX)	47.0	3,540.7	219.7	-253.9	-120.5	-53.5	--	8.5

Shareholding Pattern

View Details

About Inozyme PharmaÂ Inc (INZY)

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically... engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Read more

CEO & Chairman

Dr. Douglas A. Treco Ph.D.
CEO & Chairman

Dr. Douglas A. Treco Ph.D.
Headquarters

Boston, MA
Website

https://www.inozyme.com

FAQs for Inozyme PharmaÂ Inc (INZY)

What is the current share price of Inozyme PharmaÂ Inc (INZY) Today?

The share price of Inozyme PharmaÂ Inc (INZY) is $4.00 (NASDAQ) as of 02-Jul-2025 09:30 EDT. Inozyme PharmaÂ Inc (INZY) has given a return of -4.76% in the last 3 years.

What is the current PB & PE ratio of Inozyme PharmaÂ Inc (INZY)?

Since, TTM earnings of Inozyme PharmaÂ Inc (INZY) is negative, P/E ratio is not available.
The P/B ratio of Inozyme PharmaÂ Inc (INZY) is 8.12 times as on 02-Jul-2025, a 57 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-1.71	3.01
2023	-3.70	1.87
2022	-0.65	0.36
2021	-2.86	1.48
2020	-6.69	2.36

What is the 52 Week High and Low of Inozyme PharmaÂ Inc (INZY)?

The 52-week high and low of Inozyme PharmaÂ Inc (INZY) are Rs -- and Rs -- as of 03-Sep-2026.

What is the market cap of Inozyme PharmaÂ Inc (INZY)?

Inozyme PharmaÂ Inc (INZY) has a market capitalisation of $ 258 Mln as on 02-Jul-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Inozyme PharmaÂ Inc (INZY)?

Before investing in Inozyme PharmaÂ Inc (INZY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.